Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously ...

Ginkgo Bioworks (DNA) stock is in focus as the company as part of a collaboration with Microsoft (MSFT)-backed OpenAI cuts ...

The cell-free protein synthesis (CFPS) market is set to reach USD 308.9 million by 2030, growing at a CAGR of 7.3%. Key growth drivers include rising demand for rapid protein production, adoption of ...

It had been thought that AI would play a big part in digital-only domains like math and coding, but cleverly connecting these ...

Ginkgo Bioworks says a new AI collaboration with OpenAI is already paying off, cutting the cost of protein production in the lab by a mea ...

Cell-free protein synthesis (CFPS) represents a transformative technology in which the molecular machinery of transcription and translation is extracted from living cells and employed in a controlled ...

The yeast Kluyveromyces lactis (K. lactis) could become a highly productive, sustainable, cost-effective energy source for cell-free protein synthesis (CFPS) as biopharmaceutical manufacturers strive ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

It’s well-established that cell-free protein synthesis (CFPS) is a highly efficient way to produce complex therapeutic proteins and that vesicle delivery systems are very effective transport systems.

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology ...